资生堂化妆品失误后面临艰难转型

日本化妆品巨头资生堂正面临数十年来最大挑战,这源于北美代价高昂的失误以及市场份额被灵活的亚洲竞争对手蚕食。六年前,该公司斥资8.45亿美元收购美国品牌Drunk Elephant,以吸引年轻客户,但由于利润和销售下滑,此后已计提超过一半的投资减值。

资生堂曾是L’Oreal和雅诗兰黛公司的强大挑战者,如今正应对数十年来最严峻的障碍。这家日本化妆品制造商遭受了北美代价高昂的失误打击,并丧失了对灵活亚洲竞争对手的市场优势地位。六年前,资生堂斥资8.45亿美元收购美国品牌Drunk Elephant,旨在吸引年轻消费群体。然而,利润和销售下滑迫使公司对该投资计提超过一半的减值。这一挫折凸显了北美市场的更广泛挑战。资生堂的困境反映了全球化妆品行业的快速变化,受社会趋势演变、产品周期加速以及韩国和中国竞争对手的影响。公司如Amorepacific和Kolmar Korea已超越资生堂,成为对美最大化妆品出口商。这些灵活企业已胜过这家日本公司,展示了美容品牌在动态市场中如何迅速衰落。

相关文章

Executives from Puig and Estée Lauder shaking hands amid $40B merger talks, with stock charts showing price swings and luxury beauty products on display.
AI 生成的图像

Puig and Estée Lauder in talks for potential $40 billion merger

由 AI 报道 AI 生成的图像

Puig and The Estée Lauder Companies disclosed after Monday's market close that they are discussing a possible business combination, with no agreement reached. Puig notified Spain's CNMV on March 23, 2026. The deal could create a $40 billion beauty group with $20 billion in combined sales, prompting Estée Lauder shares to drop 7.7% while Puig's rose 11%.

Japanese retailer Muji is betting on its value-for-money skincare products to drive growth at home and abroad. These items, featuring simple formulations and transparent labeling, have doubled in revenue recently. The company targets a significant operating profit increase by 2028.

由 AI 报道

Unilever CEO Fernando Fernández has led a comprehensive corporate overhaul for a year. The food division was recently spun off for $66 billion into a joint venture with a US spice company. The focus shifts to beauty, wellness, and personal care.

Japan’s Nikkei share average fell 0.6% on February 17, 2026, to 56,451.43, dragged by SoftBank Group’s decline as post-election enthusiasm waned and U.S. markets were closed for Presidents’ Day, leaving investors short on trading cues. The index marked a fourth consecutive session of losses. Analysts pointed to a lack of catalysts and technical factors as the main drivers.

由 AI 报道

Sun Pharmaceutical Industries' shares surged more than 9% following the announcement of its $11.75 billion acquisition of US-based Organon & Co. The deal targets bolstering the Indian company's innovative medicines and positioning it strongly in biosimilars and women's health markets. Organon is recognized as a global leader in women's health.

此网站使用 cookie

我们使用 cookie 进行分析以改进我们的网站。阅读我们的 隐私政策 以获取更多信息。
拒绝